Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
2007 1
2009 1
2010 1
2011 1
2012 1
2018 1
2021 1
2022 2
2023 1
2024 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Dose-Dependent Suppression of Human Glioblastoma Xenograft Growth by Accelerator-Based Boron Neutron Capture Therapy with Simultaneous Use of Two Boron-Containing Compounds.
Kanygin V, Razumov I, Zaboronok A, Zavjalov E, Kichigin A, Solovieva O, Tsygankova A, Guselnikova T, Kasatov D, Sycheva T, Mathis BJ, Taskaev S. Kanygin V, et al. Among authors: solovieva o. Biology (Basel). 2021 Nov 2;10(11):1124. doi: 10.3390/biology10111124. Biology (Basel). 2021. PMID: 34827117 Free PMC article.
Decoding NY-ESO-1 TCR T cells: transcriptomic insights reveal dual mechanisms of tumor targeting in a melanoma murine xenograft model.
Alsalloum A, Alrhmoun S, Perik-Zavosdkaia O, Fisher M, Volynets M, Lopatnikova J, Perik-Zavodskii R, Shevchenko J, Philippova J, Solovieva O, Zavjalov E, Kurilin V, Shiku H, Silkov A, Sennikov S. Alsalloum A, et al. Among authors: solovieva o. Front Immunol. 2024 Nov 26;15:1507218. doi: 10.3389/fimmu.2024.1507218. eCollection 2024. Front Immunol. 2024. PMID: 39660132 Free PMC article.
A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.
Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP; Motavizumab Cardiac Study Group. Feltes TF, et al. Pediatr Res. 2011 Aug;70(2):186-91. doi: 10.1203/PDR.0b013e318220a553. Pediatr Res. 2011. PMID: 21522037 Clinical Trial.
13 results